Strategic partnerships Curi Bio has a published strategic partnership with Battelle to commercialize neuromuscular junction assay technology, signaling an opportunity to engage in co-development, licensing, or expansion of joint offerings in human-relevant NMJ platforms.

Curiverse launch The Curiverse closed-loop ecosystem combines iPSC-derived cells, automated high-throughput systems, and cloud analytics, suggesting sales potential for end-to-end platforms, integration services, and scalable data analytics for industrial-scale drug discovery.

Neuromuscular focus Recent NMJ assay technology generation and HCM isogenic pair indicate emphasis on cardiac and neuromuscular disease models, presenting upsell opportunities for specialized tissue models, companion assays, and disease-relevant readouts.

High-throughput readiness Nautilai Plus unifies contractility and optical readouts in a 96-well format, highlighting potential for customers seeking high-throughput, reproducible phenotypic assays and scalable screening capabilities.

Global collaboration Strategic announcements at MPS 2026 and World Summit position Curi Bio as a thought leader in human-relevant data, offering avenues to pursue enterprise deals, channel partnerships, and platform-wide collaborations with CROs and pharma.